Literature DB >> 19786997

Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.

Kein-Leong Yim, David Cunningham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19786997     DOI： 10.1038/nrclinonc.2009.140

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

2.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Authors:  Christophe Tournigand; Andres Cervantes; Arie Figer; Gérard Lledo; Michel Flesch; Marc Buyse; Laurent Mineur; Elisabeth Carola; Pierre-Luc Etienne; Fernando Rivera; Isabel Chirivella; Nathalie Perez-Staub; Christophe Louvet; Thierry André; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

3.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

4.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

Review 5.  Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.

Authors:  Mohamed Hebbar; Marc Ychou; Michel Ducreux
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-03       Impact factor: 4.553

6.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Authors:  Alberto F Sobrero; Joan Maurel; Louis Fehrenbacher; Werner Scheithauer; Yousif A Abubakr; Manfred P Lutz; M Eugenia Vega-Villegas; Cathy Eng; Ernst U Steinhauer; Jana Prausova; Heinz-Josef Lenz; Christophe Borg; Gary Middleton; Hendrik Kröning; Gabriele Luppi; Oliver Kisker; Angela Zubel; Christiane Langer; Justin Kopit; Howard A Burris
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544

7.  Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

Authors:  F-C Bidard; C Tournigand; T André; M Mabro; A Figer; A Cervantes; G Lledo; L Bengrine-Lefevre; F Maindrault-Goebel; C Louvet; A de Gramont
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

8.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

9.  A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.

Authors:  M Mabro; P Artru; T André; M Flesch; F Maindrault-Goebel; B Landi; G Lledo; A Plantade; C Louvet; A de Gramont
Journal:  Br J Cancer       Date:  2006-05-08       Impact factor: 7.640

10.  Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822
  10 in total
  2 in total

1.  RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.

Authors:  Xin-Xiang Li; Hong-Tu Zheng; Jun-Jie Peng; Li-Yong Huang; De-Bing Shi; Lei Liang; San-Jun Cai
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

2.  The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.

Authors:  Justin Greene; Anna Nguyen; Stacey M Bagby; Gemma N Jones; W M Tai; Kevin S Quackenbush; Anna Schreiber; Wells A Messersmith; Kalpana M Devaraj; Patrick Blatchford; S Gail Eckhardt; Elaine B Cadogan; Gareth D Hughes; Aaron Smith; Todd M Pitts; John J Arcaroli
Journal:  Oncotarget       Date:  2017-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.